<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03825705</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-Ib-05</org_study_id>
    <nct_id>NCT03825705</nct_id>
  </id_info>
  <brief_title>A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma</brief_title>
  <official_title>Phase Ib Clinical Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-arm, open-label clinical trial, focus on the safety and efficacy of TQB2450
      injection combined with Anlotinib hydrochloride capsule in patients with advanced biliary
      adenocarcinoma/hepatocellular carcinoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate(ORR)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Overall Response Rate (ORR) defined as the proportion of subjects who achieves a best response of CR or PR, assessed by RECIST1.1/irRECIST</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Anlotinib + TQB2450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450 injection</intervention_name>
    <description>TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.</description>
    <arm_group_label>Anlotinib + TQB2450</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>A multi-target receptor tyrosine kinase inhibitor</description>
    <arm_group_label>Anlotinib + TQB2450</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Over 18 years old; ECOG physical condition: 0 - 1 points; expected survival time more
             than 3 months; 2、Histologically or pathologically confirmed patients with unresectable
             or metastatic cholangiocarcinoma, including intrahepatic cholangiocarcinoma (IHCC),
             extrahepatic cholangiocarcinoma (EHCC) and gallbladder cancer (GBC), or advanced
             hepatocellular carcinoma (Barcelona hepatocellular carcinoma stage C, or unsuitable
             for stage B patients who failed to receive or receive local treatment); 3、Patients had
             at least one measurable lesion (RECIST 1.1); 4、Previous first-line chemotherapy failed
             in patients with adenocarcinoma of the biliary system. First-line chemotherapy failure
             is defined as disease progression during or after the last treatment, or intolerable
             side effects during treatment. (Note: a. The first-line treatment time is more than
             one cycle of combined chemotherapy drugs; B. Neoadjuvant or adjuvant chemotherapy is
             allowed in the early stage. If disease progression/recurrence occurs during
             neoadjuvant/adjuvant therapy or within 6 months after the end of treatment,
             neoadjuvant/adjuvant therapy is considered to be the first-line systemic chemotherapy
             failure for progressive diseases; C. Previous first-line standardized therapy does not
             include small molecular inhibitors of angiogenesis or monoclonal antibodies or drugs
             related to tumor immunity; Patients with hepatocellular carcinoma have not received
             systemic chemotherapy, molecular targeted drug therapy and immunotherapy; 5、Laboratory
             tests should be satisfied: routine blood tests: hemoglobin (Hb) &gt; 80g/L (no blood
             transfusion within 14 days); absolute neutrophil count (ANC) &gt; 1.5 *109/L; platelet
             (PLT) &gt; 75 *109/L; biochemical tests: alanine aminotransferase (ALT) and glutamic
             oxaloacetate aminotransferase (AST) = 2.5 *ULN (liver metastasis of tumors, &lt; 5 *ULN);
             serum total bilirubin (TBIL) = 2 *ULN (Gil) Patients with Bert syndrome, &lt; 3 *ULN;
             serum creatinine (Cr) = 1.5 *ULN and creatinine clearance rate &gt; 50 umol/L;
             coagulation function: activated partial thromboplastin time (APTT), international
             standardized ratio (INR), prothrombin time (PT) = 1.5 *ULN; Doppler ultrasound
             evaluation: left ventricular ejection fraction (LVEF) &gt; 50%; Child-Pugh Liver Function
             Rating for Patients with Liver Cancer: A-B (&lt; 8 points), (Child-Pugh Albumin Rating
             must be less than 2 points, i.e. more than 28g/L; Bilirubin Rating 1 point, TBIL &lt;
             2.0xULN; Ascites Rating &lt; 2 points; Hepatic Encephalopathy &lt; 1 point; Prothrombin Time
             Rating &lt; 2 points); 6、Women should agree to use contraceptive measures (such as
             intrauterine device [IUD], contraceptive pill or condom) within 6 months of the study
             period and the end of the study period; serum or urine pregnancy tests are negative
             within 7 days before the study group and must be non-breastfeeding patients; men
             should agree to use contraceptive measures during the study period and within 6 months
             after the end of the study period; 7、The patients voluntarily joined the study and
             signed the informed consent with good compliance.

        Exclusion Criteria:

          1. Patients who had previously received treatment with target inhibitors of vascular
             endothelial growth factor R, including Anlotinib hydrochloride capsules, or other
             anti-PD-1/PD-L1/CTLA-4 antibodies or other immunotherapy against PD-1/PD-L1/CTLA-4
             were treated; 2、Severe hypersensitivity was observed after administration of other
             monoclonal antibodies; 3、Within five years, the subjects had other malignant tumors
             (except cured basal cell carcinoma of skin, carcinoma in situ of prostate and
             carcinoma in situ of cervix); 4、There is any active autoimmune disease or history of
             autoimmune disease (e.g., autoimmune hepatitis, interstitial pneumonia, enteritis,
             vasculitis, nephritis; asthma patients who need bronchiectasis for medical
             intervention can not be included); but the following patients are allowed to enter the
             group: vitiligo without systemic treatment, psoriasis, alopecia, well-controlled I. In
             type 2 diabetes mellitus, hypothyroidism with normal thyroid function is treated by
             substitution therapy; 5、Immunosuppressive therapy with immunosuppressive agents or
             systemic or absorbable local hormones (dosage &gt; 10mg/prednisone or other therapeutic
             hormones) is required for the purpose of immunosuppression, and is still in use for 2
             weeks after the first administration; 6、Those with multiple factors affecting oral
             medication, such as inability to swallow, Post-gastrointestinal resection, chronic
             diarrhea and intestinal obstruction, etc; 7、Uncontrollable pleural effusion,
             pericardial effusion or ascites requiring repeated drainage; 8、Regardless of the
             severity, patients with any physical signs or history of bleeding, patients with
             bleeding or bleeding events greater than or equal to CTCAE 3 within four weeks prior
             to the first administration, or patients with unhealed wounds, fractures, gastric and
             duodenal active ulcers, ulcerative colitis, or unresected tumors have active bleeding,
             or may be caused as determined by the researchers. Other conditions of
             gastrointestinal bleeding and perforation;9、Brain metastases were detected by CT or
             MRI at screening, and there was a history of organ transplantation;10、Within four
             weeks before the start of the study, the patients received approved or in-progress
             antineoplastic therapy, including but not limited to chemotherapy, surgery,
             radiotherapy, biological targeted therapy, interventional therapy, immunotherapy and
             antineoplastic traditional Chinese medicine treatment (based on indications of Chinese
             medicine instructions, such as 2-week elution period can also be included in the
             group), etc. (Note: Oral targeting drugs with less than 5 half-lives or oral
             fluorouracil; Patients with pyridine drugs for less than 14 days, mitomycin C and
             nitrosourea for less than 6 weeks, and patients whose adverse events (except hair
             loss) caused by previous treatment did not recover to &lt; CTCAE 1 degree;11、Patients
             with any serious and/or uncontrollable disease, including:(a) Patients with
             unsatisfactory blood pressure control (systolic blood pressure (&gt; 150 mmHg), diastolic
             blood pressure (&gt; 90 mmHg);(b) Thrombotic events, ischemic attacks, myocardial
             infarction, grade 2 congestive heart failure or arrhythmias requiring treatment
             (including QTc (&gt; 480ms) occurred within 6 months of first administration;(C) Severe
             active or uncontrolled infections (&gt; CTC AE 2 infection), tuberculosis patients;(D)
             Known clinical history of liver diseases, including viral hepatitis, known carriers of
             hepatitis B virus (HBV) must exclude active HBV infection, that is, HBV DNA positive
             (&gt; 1 *104 copies/mL or &gt; 2000 IU/mL); known hepatitis C virus infection (HCV) and HCV
             RNA positive (&gt; 1 *103 copies/mL), or other decompensated hepatitis and chronic
             hepatitis, which require antiviral treatment. Therapy;(E) HIV positive;(F) poor
             control of diabetes mellitus (fasting blood sugar (&gt; CTCAE 2);(G) Urinary routine
             indicated that urinary protein (++) and confirmed 24-hour urinary protein
             quantification (&gt;1.0 g);12、Vaccinated with vaccines or attenuated vaccines within 4
             weeks after first administration; 13、According to the judgement of the researchers,
             there are other factors that may lead to the termination of the study. For example,
             other serious diseases (including mental disorders) need to be treated together, there
             are serious abnormal laboratory examinations, accompanied by family or social factors,
             which will affect the safety of the subjects, or the collection of data and samples.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aiping Zhou</last_name>
    <phone>010-87788800</phone>
    <email>zhouap1825@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aiping Zhou</last_name>
      <phone>010-87788800</phone>
      <email>zhouap1825@126.com</email>
    </contact>
    <investigator>
      <last_name>Aiping Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

